Post-endoscopic retrograde cholangiopancreatography bowel evisceration in a liver transplant recipient previously
Elena Santos-Pérez1, Cecile Gomercic2, Maxime Thobois2
1Endoscopy , University Hospital of Nice, France.
Abstract:
Hepatocellular carcinoma (HCC) treatment increasingly involves liver transplantation (LT), often after downstaging therapies. Atezolizumab, a PD-L1 inhibitor, combined with bevacizumab, an anti-VEGF agent, is widely used, showing high response rates pre-transplant. However, bevacizumab impairs angiogenesis and can significantly increase the risk of wound dehiscence, infection, and delayed healing after major surgery, including LT.
More Related Videos
13:57Laparoscopic Anatomical Liver Segment VII Resection with Liver Parenchymal Transection Following a Priority Approach
Published on: May 23, 2025
04:05Endoscopic Vacuum Therapy for the Treatment of Anastomotic Leakage after Total Gastrectomy with Esophagojejunostomy
Published on: August 22, 2025
